Kaspersky is addressing one of the most debatable technological challenges of the coming decade: the rise of quantum ...

Drug discovery has traditionally been slow and expensive, often taking decades and costing manufacturers billions. But with quantum computing, that's all changing.

IonQ should be the preferred choice over D-Wave Quantum since the company has a larger intellectual property portfolio, including 950 patents related to quantum computing.

D-Wave Quantum (NYSE: QBTS), an early mover in the quantum computing market, went public by merging with a special purpose ...

More than 100 companies, including Deloitte, Mastercard, Lockheed Martin, and Accenture, use its services. Its own modular Advantage QPUs are built to handle quantum annealing tasks.

D-Wave Quantum (NYSE: QBTS), a quantum computing company, has seen its stock price surge by an impressive 1,360% in the last twelve months, reflecting the increasing interest in this potentially ...

Israeli quantum computing startup Classiq has raised $110 million in a mid-stage private funding round, it said on Monday, bringing its total fundraising to $173 million.

The company’s forthcoming quantum processor, IBM Starling, was unveiled today, with officials saying it promises efficiency without burdensome overhead.

Both D-Wave Quantum and IonQ could have tremendous growth potential. Quantum computing could transform many areas, including drug discovery, logistics, and materials science.

D-Wave Quantum also boasts a strong customer base with notable clients, such as Lockheed Martin CorporationLMT and Deloitte (read more: Here's Why D-Wave Stock Promises High Growth and Is a Buy).